prikaz prve stranice dokumenta PCSK9 inhibitors in clinical practice: Expectations and reality
Access restricted to students and staff of home institution
Scientific paper - Other
PCSK9 inhibitors in clinical practice: Expectations and reality
Atherosclerosis (Amsterdam), 270 (2018); 187-188. https://doi.org/10.1016/j.atherosclerosis.2018.01.001
Reiner, Željko

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Reiner, Ž. (2018). PCSK9 inhibitors in clinical practice: Expectations and reality. Atherosclerosis (Amsterdam), 270., 187-188. doi: 10.1016/j.atherosclerosis.2018.01.001

Reiner, Željko. "PCSK9 inhibitors in clinical practice: Expectations and reality." Atherosclerosis (Amsterdam), vol. 270, 2018, pp. 187-188. https://doi.org/10.1016/j.atherosclerosis.2018.01.001

Reiner, Željko. "PCSK9 inhibitors in clinical practice: Expectations and reality." Atherosclerosis (Amsterdam) 270 (2018): 187-188. https://doi.org/10.1016/j.atherosclerosis.2018.01.001

Reiner, Ž. (2018) 'PCSK9 inhibitors in clinical practice: Expectations and reality', Atherosclerosis (Amsterdam), 270, pp. 187-188. doi: 10.1016/j.atherosclerosis.2018.01.001

Reiner Ž. PCSK9 inhibitors in clinical practice: Expectations and reality. Atherosclerosis (Amsterdam) [Internet]. 2018 [cited 2024 November 07];270:187-188. doi: 10.1016/j.atherosclerosis.2018.01.001

Ž. Reiner, "PCSK9 inhibitors in clinical practice: Expectations and reality", Atherosclerosis (Amsterdam), vol. 270, pp. 187-188, 2018. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:226642. [Accessed: 07 November 2024]

Metadata
Title (english)PCSK9 inhibitors in clinical practice: Expectations and reality
AuthorŽeljko Reiner
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
There is no doubt today that lowering LDL- cholestrol (LDL-C) reduces atherosclerotic cardiovascular disease (ASCVD) morbidity and mortality [1]. Statins are the established treatment of choice for lowering LDL-C since the early 90s and in secondary, but also primary prevention, they can reduce ASCVD morbidity and mortality [2]. Nevertheless, a number of patients, particularly those with familial hypercholesterolaemia (FH), are unable to achieve LDL-C target values, as recommended by the guidelines, even with high doses of more potent statins [3–5].
Keywords (english)
Languageenglish
Publication typeScientific paper - Other
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleAtherosclerosis (Amsterdam)
Numberingvol. 270, pp. 187-188
p-ISSN0021-9150
DOIhttps://doi.org/10.1016/j.atherosclerosis.2018.01.001
URN:NBNurn:nbn:hr:184:226642
Publication2018
Document URLhttp://bib.irb.hr/1049922
Type of resourceText
Access conditionsInstitutional access
Terms of useLicence In copyright icon
Created on2022-03-01 14:46:47